Page 73 - 2021_06-Haematologica-web

Fenofibrate reduces experimental osteonecrosis
gence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;117 (13):3585-3595.
32. Ramsey LB, Janke LJ, Edick MJ, et al. Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model. Pharmacogenet Genomics. 2014;24(5):263-271.
33. Team RDC. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. 2006.
34. Prism. GraphPad Software, version 8.2.1. La Jolla, CA, USA.
35. Kuroda T, Tanabe N, Wakamatsu A, et al. High triglyceride is a risk factor for silent osteonecrosis of the femoral head in sys- temic lupus erythematosus. Clin Rheumatol. 2015;34(12):2071-2077.
36. Mankin HJ. Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med. 1992;326(22): 1473-1479.
37. Sakamoto Y, Yamamoto T, Sugano N, et al. Genome-wide association study of idio- pathic osteonecrosis of the femoral head. Sci Rep. 2017;7(1):15035.
38. Lee YJ, Cui Q, Koo KH. Is there a role of pharmacological treatments in the preven- tion or treatment of osteonecrosis of the femoral head? A systematic review. J Bone
Metab. 2019;26(1):13-18.
39. Ito C, Evans WE, McNinch L, et al.
Comparative cytotoxicity of dexametha- sone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol. 1996;14(8):2370-2376.
40.Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lym- phoblastic leukemia. Blood. 2012;119(7): 1658-1664.
41. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001;(386): 173-178.
42. Pengde K, Fuxing P, Bin S, Jing Y, Jingqiu C. Lovastatin inhibits adipogenesis and pre- vents osteonecrosis in steroid-treated rab- bits. Joint Bone Spine. 2008;75(6):696-701.
43. Ajmal M, Matas AJ, Kuskowski M, Cheng EY. Does statin usage reduce the risk of cor- ticosteroid-related osteonecrosis in renal transplant population? Orthop Clin North Am. 2009;40(2):235-239.
44.Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11): 1500-1510.
45. PengJ,LuoF,RuanG,PengR,LiX. Hypertriglyceridemia and atherosclerosis. Lipids Health Dis. 2017;16(1):233.
46. Janke LJ, Van Driest SL, Portera MV, et al. Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. Blood. 2019;134(12):983-986.
47. Therrien R, Barret P, Robitaille M, Moghrabi A. Use of fenofibrate in asparaginase- induced hypertriglyceridemia in children with ALL: a case series. http://wwwindici- bleca/urpp/20130516_FENOFIBRATE_Anna lespdf. 2013
48.Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child. 1985;60(1):34-37.
49. Smalley CM, Goldberg SJ. A pilot study in the efficacy and safety of gemfibrozil in a pediatric population. J Clin Lipidol. 2008;2(2):106-111.
50. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: National Heart, Lung and Blood Institute. Expert panel on integrated guidelines for cardiovas- cular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213-56.
51. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipi- demic children and adolescents treated with fenofibrate. Cli Chim Acta. 1981;112(1):43- 53.
haematologica | 2021; 106(8)
2101